J Clin Pharmacol
HOME HELP FEEDBACK SUBSCRIPTIONS ARCHIVE SEARCH TABLE OF CONTENTS
QUICK SEARCH:   [advanced]


     

Sign In to gain access to subscriptions and/or personal tools.
This Article
Right arrow Full Text
Right arrow Full Text (PDF)
Right arrow Alert me when this article is cited
Right arrow Alert me if a correction is posted
Right arrow Citation Map
Services
Right arrow Email this article to a friend
Right arrow Similar articles in this journal
Right arrow Similar articles in ISI Web of Science
Right arrow Similar articles in PubMed
Right arrow Alert me to new issues of the journal
Right arrow Download to citation manager
Right arrowRequest Permissions
Right arrow Request Reprints
Citing Articles
Right arrow Citing Articles via HighWire
Right arrow Citing Articles via ISI Web of Science (27)
Right arrow Citing Articles via Google Scholar
Google Scholar
Right arrow Articles by Prisant, L. M.
Right arrow Search for Related Content
PubMed
Right arrow PubMed Citation
Right arrow Articles by Prisant, L. M.

SYMPOSIUM

Preventing Type II Diabetes Mellitus

L. Michael Prisant, MD, FACC, FACP, FCP

From the Medical College of Georgia, Augusta.

Burgeoning obesity is increasing the prevalence of type II diabetes mellitus. As a consequence, there will be an even greater burden of cardiovascular disease, end-stage renal disease, blindness, and lower extremity amputations. If diagnosed, impaired glucose tolerance presents an opportunity for intervention that potentially could delay or prevent the development of diabetes. Recent prospective studies document the effectiveness of exercise and weight reduction in preventing diabetes. Metformin is less effective than intense lifestyle interventions. Acarbose, losartan, orlistat, pravastatin, ramipril, and hormone replacement therapy are associated with lower rates of the development of diabetes. The Diabetes Reduction Assessment with Ramipril and Rosiglitazone Medication (DREAM) trial and the Nateglinide and Valsartan in Impaired Glucose Tolerance Outcomes Research (NAVIGATOR) trial were designed to assess not only the prevention of diabetes but also the impact on cardiovascular morbidity and mortality.

Key Words: Diabetes mellitus • glucose intolerance • prevention • controlled trials • lifestyle • review

Address for reprints: L. Michael Prisant, MD, 1120 Fifteenth Street, BI-5082, Hypertension and Clinical Pharmacology, Medical College of Georgia, Augusta, GA 30912.




This article has been cited by other articles:


Home page
 BMJHome page
C. L Gillies, K. R Abrams, P. C Lambert, N. J Cooper, A. J Sutton, R. T Hsu, and K. Khunti
Pharmacological and lifestyle interventions to prevent or delay type 2 diabetes in people with impaired glucose tolerance: systematic review and meta-analysis
BMJ, February 10, 2007; 334(7588): 299 - 299.
[Abstract] [Full Text] [PDF]

Home page
 ANN INTERN MEDHome page
M. J. Krantz and P. S. Mehler
Angiotensin-Converting Enzyme Inhibitors and Diuretics: Optimal Combination Therapy
Ann Intern Med, December 7, 2004; 141(11): 893 - 893.
[Full Text] [PDF]

Home page
 NEJMHome page
A. Segal and B. F. Palmer
Hyperkalemia and Inhibitors of the Renin-Angiotensin-Aldosterone System
N. Engl. J. Med., December 2, 2004; 351(23): 2450 - 2451.
[Full Text] [PDF]

Home page
 J Clin PharmacolHome page
L. M. Prisant
Diabetes Mellitus: An Imperative for Prevention and Intense Management
J. Clin. Pharmacol., April 1, 2004; 44(4): 394 - 396.
[Full Text] [PDF]


HOME HELP FEEDBACK SUBSCRIPTIONS ARCHIVE SEARCH TABLE OF CONTENTS
Copyright © 2004 by the American College of Clinical Pharmacology